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Abstract
Nerve injury during breast cancer surgery can cause neuropathic pain (NP). It is not known why some, but not all, patients develop
chronic postsurgical neuropathic pain (CPSNP) after the same nerve injury. In this study, we examined 251 breast cancer survivors
with surgeon-verified intercostobrachial nerve resection to identify factors that associate with CPSNP. The patients were recruited
from a previous study of 1000women treated for breast cancer in 2006 to 2010. This enabled us to analyze preoperative factors that
associate with future CPSNP. The patients were re-examined in 2014 to 2016 to diagnose CPSNP using the revised NP diagnostic
criteria. Preoperative assessments were pain in the area to be operated on, any chronic pain condition, depressive symptoms,
anxiety, sleep, and experimental cold pain sensitivity using the cold pressor test (CPT). Follow-up assessments were CPT,
psychological factors, sleep, any chronic pain, and basic laboratory tests. One hundred thirty-seven (55%) patients with
intercostobrachial nerve resection fulfilled CPSNP diagnostic criteria after 4 to 9 years. Of them, 30 patients (22%) had moderate to
severe pain in self-reports and 86 (63%) presentedmoderate to severe evoked pain at examination. Preoperative pain in the surgical
area, other chronic pains, and breast-conserving surgery were associated with future CPSNP. Other chronic pains, increased
psychological burden, and insomnia, both before surgery and at the follow-up, were associated with CPSNP. Preoperative CPT did
not associate with future CPSNP. Patients with established CPSNP showed increased pain sensitivity in CPT and higher levels of
inflammatory markers, suggesting that central sensitization and inflammation may associate with the maintenance of CPSNP.
Keywords: Neuropathic pain, Intercostobrachial nerve, Breast cancer, Cold pressor tolerance, Central sensitization, Anxiety,
Depression
1. Introduction
The reported pooled prevalence estimates of chronic post-
surgical neuropathic pain (CPSNP) after breast cancer surgery
are 14% to 31% in all patients and 33% to 58% in those reporting
persistent postsurgical pain (PPSP).16,17 The intercostobrachial
nerve (ICBN) is frequently resected in breast cancer surgery,
leading to sensory abnormalities.44 However, the evidence is
conflicting about how the ICBN is handled and subsequent
pain.2,3,14,32,44
Neuropathic pain (NP) is defined as pain caused by a lesion or
a disease of the somatosensory nervous system.12 In the revised
criteria for the diagnosis of NP, surgeon-verified nerve injury is one
of the confirmatory tests for definite NP, in addition to sensory
abnormalities and pain in the corresponding area.12
Multiple mechanisms encompassing both the peripheral and
central nervous systems have been identified in the pathophys-
iology of NP,9 but these do not explain why some patients, but not
all, develop NP despite the same etiology.9,20,25 This also applies
to ICBN resection and CPSNP.20
Previous prospective studies analyzing the association of
preoperative patient-related factors and CPSNP have shown that
pain, opioid use, poorer neuropsychological function, female sex,
and anxiety associate with future CPSNP.4,11,25,26,32
In other types of NP, predictive factors are more difficult to assess
because the onset of nerve injury is not as well-defined as in CPSNP.
However, other NP conditions provide cross-sectional information of
neuropathic patients with or without pain. In diabetes, the role of
inflammation is of significant interest in both polyneuropathy and
NP.34 Interestingly, different inflammatory profiles have been reported
in painful vs nonpainful diabetic polyneuropathy.10,45 To our
knowledge, there are no studies on the role of inflammation in painful
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vs nonpainful traumatic nerve injury. However, higher cytokine levels
in the cerebrospinal fluid have been measured in patients with
traumatic NP compared with healthy controls.7
Lipid profiles differ in HIV patients with or without neuropathy.33
However, their role has not been clarified in painful vs nonpainful
neuropathy. Elevated plasma glucose levels have been reported
to associate with daily chronic pain,31 but not with painful
compared with nonpainful diabetic polyneuropathy.34
No study has assessed the role of general pain sensitivity,
measured with the cold pressor test (CPT) before surgery, to predict
development ofCPSNP.However, patientswith establishedCPSNP
have been reported to be more pain sensitive in the CPT compared
with those who do not have NP after similar nerve transection.42
To study factors that may differentiate patients with or without
CPSNP after ICBN resection, we used the data from a previous
study of 1000 patients treated for breast cancer21 and invited
those having a surgeon-defined ICBN resection for a new
examination 4 to 9 years after surgery to confirm whether the
patients had the diagnosis of definite CPSNP or not. To study
group differences, we repeated the preoperative assessments of
pain sensitivity and tolerance using CPT, presence of any chronic
pain, distress, and self-reported sleep disturbances. In addition,
we measured inflammatory biomarkers, glucose, and lipid levels
in plasma at the follow-up.
2. Patients and methods
2.1. Original cohort: preoperative and treatment-
related variables
The patients in the current study were recruited from a previous
original cohort of 1000 women operated on for unilateral breast
cancer during 2006 to 2010 at the Helsinki University Hospital.
The patient selection and study procedures of this original cohort
have previously been described in detail.21 In brief, women
scheduled for surgery of nonmetastasized unilateral breast
cancer without neoadjuvant treatment or immediate breast
reconstruction were invited. The preoperative and follow-up visit
assessments are listed in Table 1.
Experimental heat pain sensitivity was analyzed with a 16 3 16-
mm thermode (TSA-II NeuroSensory Analyzer; Medoc Ltd, Ramat
Yishai, Israel). In the heat pain test, the patients reported their pain
intensity with a Numerical Rating Scale (NRS 0-10) after a 5-second
stimulation with 43˚C and 48˚C. Cold pain sensitivity and tolerance
were assessed using the CPT. Patients immersed their contralateral
(to the side to be operated on) hand into circulating cold water (12-
4˚C) bath (JULABO USA Inc, Allentown, PA) up to the wrist for the
maximum time tolerated but no longer than 90 seconds (referred to
as cold pain tolerance). During the CPT, patients reported pain
intensity every 15 seconds and at the end of CPT on anNRS 0 to 10
(referred to as cold pain sensitivity).
The surgical procedure was either mastectomy or breast-
conserving surgery (BCS) with sentinel lymph node biopsy
(SLNB) or axillary lymph node dissection (ALND). Clinically
node-negative patients with radiologically unifocal tumors not
exceeding 30mm in size underwent SLNB. Generally, all patients
with tumor-positive sentinel nodes underwent completion ALND.
Patients with large (.30 mm) or multifocal tumors in breast
imaging, as well as clinically node-positive patients, underwent
direct ALND of Berg levels I and II. Level III was also dissected if
clinically suspicious nodes were present. Surgery was performed
or directly supervised by experienced breast surgeons. The
operating surgeon documented whether ICBN was preserved,
totally or partially resected, or not visualized during surgery.
Anesthesia was standardized with remifentanil, propofol, and
rocuronium. Postoperatively, the patients were given acetamino-
phen 1 g every 8 hours, and they were titrated pain-free with
intravenous oxycodone, first by the research nurse at the
postanesthesia care unit (PACU) and then with patient-controlled
analgesia on the ward.21 Data on pain intensity before oxycodone
titration and consumption of oxycodone during the 2-hour period at
the PACU were collected. Data concerning oncological treatments,
reoperation, and breast reconstructions were collected.
2.2. Current cohort: patients with injury of the
intercostobrachial nerve
To address the question of why some patients but not all develop
CPSNP after similar nerve injury, we, in this study, included
patients with a surgeon-verified, total, or partial ICBN resection. In
the original cohort of 1000 patients, 440 patients underwent
either total or partial ICBN resection. Forty-one patients (9.3%)
had died, and 38 patients (8.6%) had reached 75 years of age at
the time of recruitment and were therefore not invited. Eight
patients (1.8%) were excluded for other reasons (eg, no breast
cancer at final histology). Thus, 353 patients (353/440, 80.2%)
were eligible for the follow-up visit. The research nurse contacted
these patients through telephone to ask about their willingness to
participate in the study. Of the 353 patients, 37 (10.5%) could not
be reached and 65 patients (18.4%) declined. Thus, 251 patients
(251/440, 57%) participated. The participants (N 5 251) and
eligible nonparticipants (N 5 102) did not differ in terms of
preoperative and treatment-related variables (see supplementary
Table 1, supplemental digital content, available at http://links.
lww.com/PAIN/A661, which demonstrates comparison of par-
ticipants and eligible nonparticipants). Figure 1 illustrates the
complete patient flow.
The study was approved by the Coordinating Ethics Board of
the Helsinki and Uusimaa Hospital District and registered in
ClinicalTrials.gov (NCT02487524). All patients gave informed
written consent.
2.3. Follow-up visit—clinical examination and grading
criteria for definite neuropathic pain due to injury of
intercostobrachial nerve
The 251 patients with surgeon-verified injury to the ICBN
underwent a thorough sensory examination of the upper body
at the follow-up. Sensory examination consisted of testing tactile
sensation by a cotton tuft, static allodynia by finger compression,
dynamic allodynia by a painter’s brush, pinprick sensation by
a sharp wooden cocktail stick, and cold and warm sensation by
a metal roller. The affected side was compared with the
contralateral side and the surrounding skin. The examination
consisted of the following sensory modalities: hypoesthesia
(diminished sensitivity), hyperesthesia (heightened sensitivity),
dysesthesia (unpleasant sensation), and allodynia (pain evoked
by normally painless stimuli). If evoked pain was observed during
examination, the patients were asked to rate the pain intensity
(NRS 0-10). The examining neurologist was blinded to the ICBN
status of the patients during the sensory evaluation. To identify
pain in the surgical area, we used the pain intensity rating 1 or
higher (NRS 0-10) in at least one of the following 2measures: Brief
Pain Inventory (BPI) for the worst pain during past week or evoked
pain in the clinical sensory examination. The patient located the
pain to a body map drawing and the examining neurologist
located the sensory findings to a similar body map drawing of the
upper body.
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We used the revised stepwise grading criteria for NP12 to
identify patients with CPSNP. The steps include A) a history of
relevant neurological lesion and neuroanatomically plausible pain
distribution, B) that the pain associates with sensory signs in the
same neuroanatomical distribution, and C) that a diagnostic test
confirms the lesion in the somatosensory nervous system.
According to the recent revision of the grading system,
a surgeon’s report of nerve resection is equivalent to a diagnostic
test in the case of postsurgical neuropathic pain.12
All patients in this study had a history of breast cancer surgery
and ICBN resection. The region of interest was the innervation
area of the ICBN: axilla, medial upper arm, flank of chest, and
lateral breast.2 Patients were classified as “unlikely CPSNP” if no
pain was present or the localization of pain was not neuro-
anatomically plausible for the surgical area (criterion A not met).
Patientswith pain in the surgical areawithout sensory abnormality
in the corresponding region were classified as possible CPSNP
(criterion B not met). The patients with either self-reported or
evoked pain in the surgical area with at least one sensory
abnormality in the corresponding region were classified as
definite CPSNP if these findings occurred in the area of ICBN
innervation2 (criteria A, B, and C fulfilled). If the patients had pain
and sensory abnormalities in the surgical area, but outside the
ICBN innervation (eg, medial breast), they were classified as
probable CPSNP (criterion C not met).
We excluded the possible CPSNP (N 5 32) and probable
CPSNP (N5 15) groups from the analyses to avoid possible bias
caused by uncertain NP diagnosis (Fig. 1). In the final analysis we
had only patients with definite CPSNP (CPSNP group) or unlikely
CPSNP (non-CPSNP group). Two patients from each group were
excluded because of ongoing cancer treatments. We analyzed
differences in these 2 groups to understand what makes a similar
nerve injury painful or not. Thus, we had a nested case–control
design including patients having had a previous ICBN resection
with or without current CPSNP.
2.4. Demographic factors, questionnaires, and cold
pressor test
Demographic factors preoperatively and at the follow-up visit are
presented in Table 1. Preoperatively, the question of insomnia was
included after the study had started, and therefore, data are missing
from 33 patients. For pain intensity, we considered NRS $4/10 as
moderate to severe pain. At the follow-up visit, BPI for other pains
was included after the start of the study, and therefore, data are
missing from 26/251 (10%) patients. The patients reported other
chronic pains with an open question and a pain drawing. Based on
these, other pains at the follow-up were categorized as follows:
headaches, pain in the joints, back, neck, or other area.
For the psychological and sleep questionnaire outcomes, we
used cutoff values for clinically relevant outcomes to report the
proportion of patients with clinically significant symptoms. These
were used as follows: $10 for at least mild and $19 for at least
moderate depressive symptoms in the Beck’s Depression Inventory
II (BDI II)5,29; 8 to 10 for borderline and $11 for clinically significant
anxiety/depression in HADS6,29;$40 for clinically significant anxiety
in STAI39; $8 for mild to severe insomnia in ISI30; and $30 for
clinically significant catastrophizing in PCS.40 Cronbach’s alphas for
these are reported in the supplementary Table 2 (available at http://
links.lww.com/PAIN/A661).
The fasting blood samples for glucose level, lipids, vitamin D, and
inflammatory markers (high-sensitivity CRP [hs-CRP]; orosomucoid
[ORM]) were drawn at the follow-up and analyzed according to the
standard laboratory protocol (HUSLAB, Helsinki, Finland). The CPT
was performed similarly preoperatively and at the follow-up, by the
same research nurse, protocol, and equipment.
Table 1
Assessments at preoperative and follow-up visits.
Preoperative Follow-up 4–9 y after operation
Demographics Age, BMI Age, BMI, marital status, education, smoking,
alcohol consumption, and use of medication (self-
report)
Pain and sensory changes in the operative area
Neuropathic pain diagnosis N/A According to revised diagnostic grading criteria
(Finnerup et al., 2016)
Clinical sensory examination of the upper
body
N/A Static mechanical allodynia, light touch, dynamic
touch, pinprick, and thermal sensation
Pain intensity in the operative area 0-10 NRS, worst pain past week 0-10 NRS, worst pain past week
Evoked pain in the operative area N/A 0-10 NRS, at clinical examination
Other pain
Other chronic pain conditions Yes/No Pain in the following locations (yes/no): back, joints,
neck, head, and other
Intensity of other pain 0-10 NRS, worst pain past week 0-10 NRS, worst pain past week
Mood and sleep
Depressive symptoms BDI II BDI II, HADS-D
Anxiety STAI state and trait HADS-A
Insomnia Not at all/at least once a wk/every night ISI
Pain catastrophizing N/A PCS
Experimental pain
Heat pain Heat pain at 43˚C and 48˚C N/A
Cold pain CPT CPT
Blood samples N/A GHb-A1c, lipids, 25-hydroxyvitamin-D, hs-CRP,
and ORM
BDI II, Beck’s Depression Inventory II; BMI, body mass index; CPT, cold pressor test; GHb-A1c, glycated hemoglobin A1c; HADS-A, Hospital Anxiety and Depression Scale–Anxiety; HADS-D, Hospital Anxiety and Depression
Scale–Depression; hs-CRP, high-sensitivity C-reactive protein; ISI, insomnia severity index; N/A, not assessed; NRS, numerical rating scale; ORM, orosomucoid; PCS, pain catastrophizing scale; STAI, State-Trait Anxiety Inventory.
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2.5. Statistical analysis
We used Student t test for normally distributed continuous
variables in pairwise comparisons and repeated measures.
Mann–Whitney U test and x2-tests were used for non-normally
distributed and categorical variables, respectively. Spearman’s
rho (rs) was used for correlations and Cronbach’s alpha for
reliability assessments.
TopredictCPSNPwithpreoperative andbreast cancer treatment–
related clinical variables, the variables reaching P , 0.05 in the
bivariate analysis were entered as predictors in a logistic regression
analysis using the forward stepwisemethod. In addition,we tested the
model with the backward stepwise method to control for multi-
collinearity.We combined the type of breast surgery and radiotherapy
as a single categorical variable for the regression analysis because
nearly all patientswithBCS receive radiotherapy.Continuousvariables
were not categorized for this analysis. To detect the effect of possible
multicollinearity, we tested entering the susceptible variables (BDI II,
STAI state, and trait) one by one and in different combinations.
Figure 1. Patient selection and clinical grading for chronic postsurgical neuropathic pain. Surgical area refers to the breast, axilla, upper side of the chest, and
medial arm in the operated side. The area of ICBN resection refers to the lateral side of the breast, axilla, upper side of the chest, and medial arm in the operated
side. CPSNP, chronic postsurgical neuropathic pain; ICBN, intercostobrachial nerve.
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To assess the role of preoperative thermal pain sensitivity in
predicting future CPSNP, we conducted a logistic regression
analysis. Preoperatively measured variables for age, body mass
index (BMI), chronic pain (yes/no), depression (yes/no, cutoff$19
in BDI II), and anxiety (yes/no, cutoff $40 in STAI state) were
entered as covariates to control for possible confounding.
To analyze the cold pain sensitivity and tolerance in established
CPSNP 4 to 9 years after breast cancer surgery, we conducted
a Cox-regression analysis. We used (1) time to withdrawal and (2)
time to NRS 10 during CPT as the time to event. Data were right-
censored if the participant endured the CPT the maximum of 90
seconds or if NRS values did not reach 10 during CPT. Variables
measured at the research visit 4 to 9 years after surgery, including
age, BMI, other pain of at least moderate intensity (yes/no),
depression (yes/no, cutoff $19 in BDI II), and anxiety (yes/no,
cutoff $11 in HADS-A), were added as covariates to control for
possible confounding. We performed an interaction analysis for
inflammatory markers (hs-CRP and ORM) and CPSNP on CPT
parameters using cross-product terms in Cox models. Inflam-
matory markers were inserted into the model as continuous
variables.
Two-tailed P # 0.05 was considered statistically significant.
Statistical analyses were performed using SPSS 22.0 version for
Windows (SPSS Inc, Chicago, IL).
3. Results
3.1. Clinical grading of chronic postsurgical neuropathic pain
and patients with definite chronic postsurgical
neuropathic pain
Figure 1 shows the distribution of patients to unlikely, possible,
probable, and definite CPSNPgroups. In definite CPSNPpatients
(135), evoked pain at examination presented in 114 (84%)
patients and wasmostly static allodynia (99%). Pain intensity was
moderate to severe in 30 of 135 (22%) BPI reports.
3.2. Factors associating with established chronic
postsurgical neuropathic pain: patients with and without
chronic postsurgical neuropathic pain 4 to 9 years
after surgery
The intergroup comparisons of demographic factors, other pains,
psychological factors and sleep questionnaires, and laboratory
parameters are shown in Table 2. The groups were homogenous
in terms of age, time from surgery, and other demographic
factors. Body mass index was significantly higher in CPSNP
patients compared with non-CPSNP patients (Table 2).
The CPSNP patients had significantly more other pain
conditions than non-CPSNP patients (Table 2), particularly joint,
back, and neck pains. The CPSNP patients hadmore other pains
and reported higher intensities for other chronic pains: moderate
to severe pain was reported by 52/118 (44%, 17 missing values)
of CPSNP patients compared with 12/60 (20%, 5missing values)
by non-CPSNP patients (P 5 0.003).
Only a few patients in either group reported current use of NP
medications (ie, tricyclics, serotonin–norepinephrine reuptake
inhibitors, and gabapentinoids), whereas the use of other pain
medications such as nonsteroidal anti-inflammatory drugs
(NSAIDs) was more prevalent among CPSNP patients compared
with non-CPSNP patients (Table 2).
The CPSNP group reported significantly more symptoms in all
questionnaires related to psychological factors and sleep
(Table 2). A total of 60/131 (45%, 4 missing values) of the
CPSNP patients reported at least mild depressive symptoms in
BDI II compared with 14/65 (22%) of non-CPSNP patients (P 5
0.001). A total of 33/134 (25%, one missing value) of CPSNP
patients compared with 7/65 (11%) of non-CPSNP patients
showed borderline or clinically significant levels of anxiety (P 5
0.025). A total of 67/132 (51%, 3missing values) CPSNP patients
and 20/65 (31%) non-CPSNP patients suffered from at least mild
insomnia (P 5 0.008).
The CPSNP patients had significantly higher levels of hs-CRP
and ORM (Table 2). There were no differences between the
groups in other biochemical parameters (Table 2). The levels of
hs-CRP correlated positively with BMI in both groups: rs 0.374
and P, 0.001 in CPSNP group; rs 0.344 and P5 0.005 in non-
CPSNP group. Orosomucoid and BMI showed a weaker positive
correlation: rs 0.175 and P5 0.045 in CPSNP group; rs 0.239 and
P 5 0.055 in non-CPSNP group.
3.3. Preoperative and treatment-related factors associating
with future chronic postsurgical neuropathic pain
Table 3 depicts the intergroup comparison of factors related to
cancer and its treatment. In both groups, most patients (CPSNP:
124/135, 92%; non-CPSNP: 57/65, 88%) had undergone axillary
clearance. Partial resections of ICBN were more frequent than
total resections. The CPSNP patients had undergone BCS and
received radiotherapy more frequently than the non-CPSNP
patients. There was no difference between the groups regarding
administration of chemotherapy or hormonal therapy (Table 3).
Preoperatively, future CPSNP patients showed higher BMI,
reported more pain in the surgical area and elsewhere, had more
depressive symptoms and anxiety, and reported insomnia more
frequently than future non-CPSNP patients (Table 4). In addition,
CPSNP patients presented with higher immediate postoperative
pain intensity ratings and higher oxycodone consumption at the
PACU. In multivariate analysis, preoperative pain in the surgical
area, the presence of chronic pain conditions, and BCS as the
type of breast surgery were associated with increased risk of
CPSNP (Table 4). The effect of the type of breast surgery
remained significant even after controlling for radiotherapy. The
results remained unaltered despite the method of stepwise
logistic regression used. Similarly, entering variables susceptible
for multicollinearity (BDI II, STAI state and trait) one by one or in
different combinations did not affect the outcome. No significant
differences in cancer type, number of metastatic lymph nodes,
nerve resection type, reoperations, or late reconstructions were
detected (Table 3).
3.4. General pain sensitivity and chronic postsurgical
neuropathic pain: preoperative and postoperative cold
pressor test and preoperative heat pain assessment
Compared with non-CPSNP patients, CPSNP patients pre-
sented with a significantly lower cold pain tolerance and higher
cold pain sensitivity postoperatively, but not preoperatively
(Table 5). Both patient groups showed a significant increase of
withdrawal times (CPSNP: mean difference 14.2 seconds, P ,
0.001; non-CPSNP: mean difference 15.6 seconds, P, 0.001),
although no significant mean differences were detected between
groups (P 5 0.716). Preoperative heat pain (48˚C) intensity
predicted CPSNP, although the association remained non-
significant after multivariate adjustment (Table 6).
A Cox-regression analysis of the postoperative CPT (Table 7)
showed that patients with CPSNP aborted the CPT significantly
earlier than non-CPSNP patients (Fig. 2). The association
remained unaltered after multivariate adjustment. Patients in the
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Table 2
Patient demographics and clinical features 4–9 years after breast cancer surgery.
CPSNP (n 5 135) Non-CPSNP (N 5 65) P
Demographics
Age, mean (SD), y 60.4 (8.01) 61.4 (8.89) 0.45*
Time from index surgery, mean (SD), mo 77.9 (13.31) 77.7 (13.35) 0.93*
BMI, mean (SD), kg/m2 26.2 (3.90) 24.1 (3.95) <0.001*
Marital status, no. (%) 0.96†
Married or cohabiting 76 (56.3) 38 (58.5)
Single 22 (16.3) 10 (15.4)
Divorced or widowed 37 (27.4) 17 (26.2)
Educational level, number (%) 0.78†
Low 18 (13.3) 9 (13.8)
Moderate 33 (24.4) 13 (20.0)
High 84 (62.2) 43 (66.2)
Smoking, number (%) 0.82†
Never smoked 66 (48.9) 30 (46.2)
Smoker 24 (17.8) 14 (21.5)
Ex-smoker 45 (33.3) 21 (32.3)
Alcohol consumption, number (%)§ 0.56†
Abstinent 20 (14.8) 13 (20.0)
,6 doses per week 84 (62.2) 36 (55.4)
$6 doses per week 30 (22.2) 16 (24.6)
Other pain conditions
Worst other pain past week, median (IQR), 0-
10 NRS‖
3 (1-5) 0 (0-2) <0.001‡
Joint pain, number (%) 82 (60.7) 21 (32.3) <0.001†
Back pain, number (%) 42 (31.1) 11 (16.9) 0.033†
Neck pain, number (%) 47 (34.8) 5 (7.7) <0.001†
Headache, number (%) 15 (11.1) 2 (3.1) 0.056†
Other pain, number (%) 67 (49.6) 15 (23.1) <0.001†
Overlapping pain conditions, number (%) <0.001†
No other pain 15 (11.1) 33 (50.8)
1 or 2 other pain conditions 80 (59.3) 27 (41.5)
3 or more other pain conditions 40 (29.6) 5 (7.7)
Current use of pain medication
Tricyclic antidepressant, gabapentinoids, or
SNRI, number (%)
6 (4.4) 3 (4.6) 0.96†
NSAID, acetaminophen, or mild opioid,
number (%)
25 (18.5) 3 (4.6) 0.008†
Mood and sleep
BDI II, median (IQR) 9 (5-14) 5 (2-9) <0.001‡
HADS-A, median (IQR) 5 (3-7) 3 (1-5) <0.001‡
HADS-D, median (IQR) 3 (1-6) 1 (0-3) 0.001‡
PCS, median (IQR) 6 (1-13) 1 (0-8) <0.001‡
ISI, median (IQR) 8 (4-12) 4 (2-9) 0.001‡
Laboratory parameters{
GHb-A1C, mean (SD), % (4.0-6.0) 5.6 (0.4) 5.5 (0.3) 0.36*
Cholesterol (total), mean (SD), mmol/l (,5.0) 5.5 (1.1) 5.6 (0.9) 0.47*
LDL, mean (SD), mmol/L (,3.0) 3.3 (0.9) 3.4 (0.8) 0.69*
HDL, mean (SD), mmol/L (.1.20) 2.01 (0.55) 2.03 (0.53) 0.75*
Triglyserides, mean (SD), mmol/L (,1.70) 1.13 (0.46) 1.20 (0.57) 0.37*
hs-CRP, median (IQR), mg/L (0.05-3.00) 0.99 (0.37-2.42) 0.53 (0.27-1.14) 0.005‡
ORM, mean (SD), mg/L (500-1200) 852 (237) 781 (178) 0.019*
25-Hydroxyvitamin-D, mean (SD), nmol/L
(.50)
76 (25) 82 (22) 0.094*
* Student t test.
† Chi-square test.
‡ Mann–Whitney U test.
§ One answer is missing from the NP group. One dose corresponds to 12 g of pure alcohol.
‖ Seventeen values are missing from the NP group and 5 from the non-NP group.
{ The normative values are shown in parenthesis.
P values, 0.05 are shown in bold. BDI II, Beck’s Depression Inventory II; BMI, body mass index; CPSNP, chronic postsurgical neuropathic pain; GHb-A1C, glycated hemoglobin A1C; HADS-A, Hospital Anxiety and Depression
Scale–Anxiety; HADS-D, Hospital Anxiety and Depression Scale–Depression; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; IQR, interquartile range; ISI, insomnia severity index; LDL, low-density
lipoprotein; NSAID, nonsteroidal anti-inflammatory drug; ORM, orosomucoid (alpha-1-acid glycoprotein); PCS, pain catastrophizing scale; SNRI, serotonin–norepinephrine reuptake inhibitors.
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CPSNP group were also more likely to score NRS 10 during CPT
compared with non-CPSNP patients (Fig. 2).
There was a significant association for cold pain tolerance and
hs-CRP (HR5 1.06, CI: 1.02-1.10,P5 0.005) but not for ORM (P
5 0.201). There was no significant interaction between CPSNP




Of the 440/1000 patients with surgeon-verified ICBN resection,
251/440 (57%) were examined 4 to 9 years after index breast
cancer surgery. Fifty-five percent of these patients (137/251)
fulfilled the diagnostic criteria for definite CPSNP. Twenty-two
percent (30/137) of them reportedmoderate to severe pain in self-
report (BPI), and 63% (86/137) had moderate to severe evoked
pain at clinical examination. Compared with the non-CPSNP
patients, CPSNP patients had more depressive symptoms,
anxiety, pain catastrophizing, impaired sleep, and other pains.
They also had higher levels of inflammatorymarkers and increased
sensitivity in the CPT, suggesting a possible role of central
sensitization. Preoperatively, CPSNP patients showed more
psychological distress, insomnia, and more pain both in the
surgical area and in other locations than the non-CPSNP patients.
4.2. Prevalence of chronic postsurgical neuropathic pain
after breast cancer surgery
TheprevalenceofNPafter breast cancer surgery ranges from33%
to 58% in those patients who have PPSP,17 depending on when
and how the diagnosis of NP is made. The diagnosis is usually
based on validated questionnaires in cross-sectional studies. So
far, few prospective assessments with clinical examination have
been conducted with follow-ups to 1 year.17,32 Our study is the
first, to our knowledge, to use the revised NP grading criteria,
combining a thorough clinical sensory examination with surgeons’
report of nerve injury to reach the diagnostic level of “definite”
CPSNP. Extensive sensory examination of multiple modalities,
especially reports of evoked pain, allowed identification of CPSNP
patients who might have been unnoticed in previous studies. In
addition, our study had a 4-year to 9-year follow-up to provide
further evidence of CPSNP being a long-lasting consequence of
nerve injury. This is in line with a previous study that showed pain
and sensory disturbances to be a marked problem after breast
cancer surgery during a follow-up of 5 to 7 years. In that study,
PPSP was reported by over a third of the patients.27
Table 3
Characteristics of breast cancer and its treatment.
CPSNP (n 5 135) Non-CPSNP (N 5 65) P
Histology, number (%) 0.27*
Ductal 94 (69.6) 40 (61.5)
Lobular 27 (20.0) 13 (20.0)
Other 14 (10.4) 12 (18.5)
Gradus, number (%) 0.40*
I 27 (20.0) 14 (21.5)
II 61 (45.2) 23 (35.4)
III 47 (34.8) 28 (43.1)
Size of the tumor, median (IQR), mm 18 (13-25) 18 (14-25) 0.96†
No. of lymph nodes evacuated, mean (SD) 20.8 (10.35) 20.8 (9.42) 0.98‡
No. of metastatic lymph nodes, median (IQR) 1 (1-4) 1 (1-2) 0.066†
Breast surgery type, number (%) <0.001*
Mastectomy 69 (51.1) 50 (76.9)
BCS 66 (48.9) 15 (23.1)
Axillary surgery type, number (%) 0.35*
SLNB 11 (8.1) 8 (12.3)
ALND 124 (91.9) 57 (87.7)
Type of ICBN resection, number (%) 0.093*
Partial 88 (65.2) 50 (76.9)
Total 47 (34.8) 15 (23.1)
Reoperation, number (%) 17 (12.6) 10 (15.4) 0.59*
Late reconstruction, number (%) 45 (33.3) 25 (38.5) 0.48*
Chemotherapy, number (%) 120 (88.9) 56 (86.2) 0.58*
Radiotherapy, number (%) 102 (75.6) 38 (58.5) 0.013*
Endocrine therapy, number (%) 116 (85.9) 54 (83.1) 0.60*
Tamoxifen, number (%) 92 (68.1) 42 (64.6) 0.62*
Aromatase inhibitor, number (%) 90 (66.7) 47 (72.3) 0.42*
* Chi-square test.
† Mann–Whitney U test.
‡ Student t test.
P values , 0.05 are shown in bold. ALND, axillary lymph node dissection; BCS, breast-conserving surgery; CPSNP, chronic postsurgical neuropathic pain; ICBN, intercostobrachial nerve; IQR, interquartile range; SLNB,
sentinel lymph node biopsy.
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4.3. Type of surgery and chronic postsurgical
neuropathic pain
Axillary lymph node dissection has emerged as an important risk
factor for PPSP in multiple studies.3,15,27,28 In this cohort, ALND
was significantly more frequent than SLNB in both groups
because ICBN resection is typically performed in ALND but not in
SLNB. However, this study demonstrates that CPSNP may also
occur in SLNB patients with ICBN resection. The small number of
SLNB patients in our cohort does not allow for multivariate
analyses of type of axillary surgery. The type of ICBN resection,
partial or total, did not associate with a higher risk of having NP
agreeing with previous studies.14
Breast-conserving surgery was associated with a higher
prevalence of CPSNP than mastectomy in multivariate analysis,
even after controlling for radiotherapy. Previous studies have also
reported high incidence of PPSP after BCS, especially in the
ipsilateral arm,3,41 which may indicate a role for ICBN lesions in
the subsequent pain. The association between the type of breast
surgery and CPSNP ismultifactorial. The access and visualization
of the axilla is usually better in mastectomy than in BCS.
Mastectomy and BCS patients differ in terms of breast cancer
characteristics–mastectomy patients have, on average, larger
tumors and more metastatic lymph nodes in the axilla. However,
these factors did not differ between CPSNP and non-CPSNP
groups (Table 3).
4.4. Preoperative factors associating with future chronic
postsurgical neuropathic pain
Preoperatively, future CPSNP patients presented more pain,
anxiety, and depressive symptoms than non-CPSNP patients.
Preoperative pain in the surgical area and other chronic pains
have previously been shown to predispose to PPSP.15,28,36,37
Similarly, we found other chronic pain and preoperative pain in the
surgical area to predispose to CPSNP. Chronic pain patients
often have significant symptom overlap, which makes assess-
ment of depressive symptoms challenging.22 Therefore, the
intergroup differences in BDI II scores in our cohort may partly
reflect the chronic pain load in the patients who developed
CPSNP. Moreover, depressive symptoms and anxiety did not
present as statistically significant in the multivariate analysis for
the prediction of CPSNP, and the impact of preoperative pain and
other chronic pains seems to override their effect in our model.
Table 4
Logistic regression model of the associations of preoperative and treatment-related factors with CPSNP after ICBN resection.
Bivariate analysis Stepwise logistic regression analysis
CPSNP (n 5 135) Non-CPSNP (n 5 65) P B OR (95% CI) P
BMI at the time of surgery, mean (SD), kg/m2 25.4 (3.90) 23.8 (3.64) 0.006*
Type of breast operation and radiotherapy,
number (%)
0.002†
BCS with radiotherapy§ 64 (47.4) 15 (23.1) 1 [reference]
Mastectomy without radiotherapy 31 (23.0) 27 (41.5) 21.79 0.17 (0.06-0.44) ,0.001
Mastectomy with radiotherapy 37 (28.1) 23 (35.4) 21.41 0.24 (0.09-0.65) 0.005
Worst pain in the surgical area past week
preoperatively, median (IQR), 0-10 NRS
2 (1-3) 0 (0-1) ,0.001‡ 0.83 2.29 (1.55-3.39) ,0.001
Worst other pain past week preoperatively,
median (IQR), 0-10 NRS
2 (1-4) 0 (0-3) ,0.001‡
Presence of any chronic pain condition
preoperatively, number (%)
40 (29.6) 4 (6.2) ,0.001† 1.64 5.16 (1.53-17.34) 0.008
Pain in the surgical area upon arrival to PACU,
median (IQR), 0-10 NRS║
3 (0-5) 0 (0-4) 0.015†
Oxycodone consumption at PACU, mg/kg 0.18 (0.10) 0.14 (0.10) 0.010*
BDI II preoperatively, median (IQR){ 9 (4-13) 5 (2-9) 0.002‡
STAI state preoperatively, mean (SD)# 41.1 (10.41) 37.8 (11.74) 0.041*
STAI trait preoperatively, mean (SD)** 37.9 (9.39) 34.7 (10.70) 0.034*
Insomnia preoperatively, number (%)†† 0.027‡
Not at all 50 (37.0) 37 (56.9)
At least once a week 40 (29.6) 16 (24.6)
Every night 24 (17.8) 5 (7.7)
Nagelkerke pseudo-R2 was 0.364. Hosmer and Lemeshow Test for the model suggests a good fit to data as P5 0.423 (.0.05). Preoperative and treatment-related variables with P, 0.05 in the bivariate analysis were
included in the logistic regression analysis. Thirty-six patients (28 from the NP group and 8 from the non-NP group) had missing values in some of the variables. Only cases with complete sets of data were included in the
analysis. The missing values were not imputed. Preoperative insomnia was the source of most missing values in the regression analysis. The outcome of the analysis remained unaltered whether or not preoperative insomnia
was included.
* Student t test.
† Chi-squared test.
‡ Mann–Whitney U test.
§ Two patients from the NP group had undergone BCS without radiotherapy and were excluded from the analysis.
║ Value missing from one non-NP patient.
{ Value missing from one NP patient.
# Values missing from one NP and one non-NP patient.
** Values missing from 2 NP patients.
†† Values missing from 21 (15.6%) NP and 7 (10.8%) non-NP patients.
BCS, breast-conserving surgery; BDI II, Beck’s Depression Inventory II; BMI, body mass index; CI, confidence interval; CPSNP, chronic postsurgical neuropathic pain; IQR, interquartile range; OR, odds ratio; PACU,
postanesthesia care unit; STAI, State-Trait Anxiety Inventory.
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4.5. Chronic pain load
Chronic postsurgical neuropathic pain patients seem to accu-
mulate pain conditions. They had significantly more multisite
pains than non-CPSNP patients. This suggests that inherent
patient-related risk factors play a role in both the development
and maintenance of CPSNP. Interestingly, increased anxiety,
pain catastrophizing, depressive symptoms, and impaired quality
of sleep in the CPSNP patients may reflect a similar biopsy-
chosocial profile previously reported in patients with chronic and
overlapping pain conditions.24
4.6. Lipids, glucose, and inflammatory markers
Lipid profiles and glucose levels did not differ between CPSNP
and non-CPSNP patients. A similar finding was reported in
patients having painful or nonpainful diabetic polyneuropathies.34
The CPSNP patients showed higher levels in inflammatory
markers (hs-CRP and ORM) compared with non-CPSNP
patients. In addition, higher levels of hs-CRP, but not ORM,
associated with increased cold pain tolerance in CPT, but with no
interaction with CPSNP. Subclinical inflammation with high hs-
CRP levels has previously been associated with lower pain
tolerance in CPT.1,35
Orosomucoid is an acute-phase protein with various immu-
nomodulatory functions, and it has been associated with neuro-
inflammation.13,18 To our knowledge, it has not been studied in
NP patients before. Further studies are needed to assess its role
in the pathogenesis of NP.
Our results suggest a role for low-grade inflammation in the
maintenance of CPSNP, in line with previous evidence for other
NP conditions.8,10,38 A recent study also showed that NP patients
have increased levels of proinflammatory cytokines in the
cerebrospinal fluid compared with healthy individuals.7 Interest-
ingly, neuroinflammation has also been associated with de-
pression, anxiety, and impaired sleep,43 which all associated with
CPSNP in our cohort.
4.7. Cold pain sensitivity and tolerance
Sensitization and chronic inflammation have been suggested as
possible mechanisms in NP. The CPT was assessed pre-
operatively and re-assessed 4 to 9 years later. To our knowledge,
there are no other studies to show consistent CPT results
preoperatively and several years after surgery. Previously, a good
test–retest reliability of the CPT was shown within a 2-week
interval.23 In this study, years after the initial CPT, patients
tolerated the cold water significantly longer (Table 5). We were
unable to identify an explanation for this. The follow-up period
was several years, and the patients had received oncological
treatments, which may have affected the cold pressor tolerance.
Nearly 90% of the patients in both CPSNP and non-CPSNP
groups had received chemotherapy.
Sensitivity to preoperative CPT was not associated with
CPSNPat 4 to 9 years postoperatively. However, postoperatively,
the CPSNP patients were significantly more sensitive and less
tolerant in the CPT than the non-CPSNP patients. A previous
cross-sectional study on CPT and PPSP suggested that other
chronic pains might override the effect of PPSP on CPT.19 Our
results, however, showed that CPSNP patients were more
sensitive in the CPT, even after multivariate adjustment of
confounding factors including other pains. In line with this, a small
previous study showed that patients having NP after ulnar or
median nerve transection had decreased pain tolerance and
increased pain sensitivity in CPT, compared with non-NP
patients.42 These results together with ours may suggest a role
for central sensitization in NP.
4.8. Strengths and limitations of the study
Strengths of this study are the relatively large and homogenous
patient cohort, with a long follow-up, with rich clinical data and
Table 6
Logistic regression analysis of preoperative experimental pain measures to predict CPSNP after ICBN resection.
Unadjusted model Fully adjusted model*
B OR (95% CI) P B OR (95% CI) P
Cold pain (n 5 187)
Withdrawal time, s 20.01 0.99 (0.98-1.00) 0.15 20.01 0.99 (0.98-1.00) 0.27
Pain intensity at withdrawal, 0-10 NRS 0.04 1.04 (0.89-1.21) 0.63 0.01 1.00 (0.85-1.19) 0.97
Heat pain (n 5 199)
Pain intensity at 43˚C, 0-10 NRS 0.21 1.24 (0.92-1.67) 0.16 0.15 1.16 (0.85-1.60) 0.35
Pain intensity at 48˚C, 0-10 NRS 0.15 1.16 (1.01-1.33) 0.03 0.10 1.10 (0.96-1.28) 0.18
Hosmer and Lemeshow Test: cold pain model P 5 0.714; heat pain model P 5 0.272 (.0.05).
* Models are adjusted for the following preoperative variables: age, BMI, chronic pain (no/yes), depression (yes/no, cutoff$19 in BDI II), and anxiety (yes/no, cutoff$40 in STAI state). P values, 0.05 are shown in bold.
B, unstandardized regression weight, BMI, body mass index; BDI II, Beck’s Depression Inventory II; CI, confidence interval; CPSNP, chronic postsurgical neuropathic pain; ICBN, intercostobrachial nerve; NRS, numeric rating
scale; OR, odds ratio; STAI, State-Trait Anxiety Inventory.
Table 5
General pain sensitivity: preoperative and postoperative cold
pressor test and preoperative heat pain test.
CPSNP Non-CPSNP P
Preoperative measurements
Heat pain intensity at 43˚C,
median (IQR), 0-10 NRS
0 (0-1) 0 (0-0) 0.14*
Heat pain intensity at 48˚C,
median (IQR), 0-10 NRS
3 (2-5) 3 (1-4) 0.020*
CPT withdrawal time†, median
(IQR), s
38 (21-89) 51 (27-90) 0.12*
CPT pain intensity at
withdrawal†, median (IQR),
0-10 NRS
9 (8-9) 9 (8-9) 0.89*
Postoperative measurements after
4-9 y
CPT withdrawal time, median
(IQR), s
65 (33-90) 90 (44-90) 0.019*
CPT pain intensity at withdrawal,
median (IQR), 0-10 NRS
9 (8-10) 8 (6-9) 0.003*
* Mann–Whitney U test.
† Ten values are missing from the CPSNP and 3 from the non-CPSNP group.
P values, 0.05 are shown in bold. CPSNP, chronic postsurgical neuropathic pain; CPT, cold pressor test;
IQR, interquartile range.
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new insights into factors predisposing to and associating with
CPSNP. All patients were clinically examined and classified
according to latest NP grading criteria. The study provides new
support for the role of central sensitization in CPSNP as shown
with decreased CPT tolerance in the CPSNP patients.
A limitation of this study is that all patients had been treated for
cancer and the results can therefore not be directly translated to
other traumatic nerve injuries. Second, some of the variables
were only cross-sectional, and no conclusions regarding causal
relationship can be drawn, eg, regarding the possible role of
preoperative inflammation. Third, the data of chronic and other
pains were collected more thoroughly at the research visit 4 to 9
years from surgery than preoperatively. Although this does not
allow for direct comparison between the time points, we can
demonstrate a clear difference between CPSNP and non-
CPSNP groups at both time points. Fourth, due to the long and
varying follow-up period, we cannot exclude the possibility that
some of the non-CPSNP could have fulfilled the NP diagnostic
criteria at some point during the follow-up. However, the time
span from the index operation did not differ significantly between
the CPSNP and non-CPSNP groups.
5. Conclusions
The CPSNP and non-CPSNP patient groups differed preopera-
tively in terms of other chronic pain, sleep, and psychological
factors. The CPSNP patients showed enhanced pain sensitivity
and decreased pain tolerance in CPT only after they had
developed NP, suggesting central sensitization. In addition to
the mounting load of chronic pain, systemic inflammation may
also have contributed to this. Our results suggest that several,
possibly interlinked, patient-related risk factors may play a signif-
icant role in the development and maintenance of chronic NP
after ICBN resection. These factors should be considered when
attempting to improve prevention and management of CPSNP.
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Figure 2. Cox-regression analysis. Survival curves for cold pain tolerance (A)
and sensitivity (B). CPSNP, chronic postsurgical neuropathic pain; NRS,
Numeric Rating Scale.
Table 7
Cox-regression analysis of cold pressor test in CPSNP and
non-CPSNP patients.
HR 95% CI P
Cold pressor tolerance
Unadjusted model
CPSNP (yes) 1.70 1.10-2.61 0.016
Fully adjusted* model
CPSNP (yes) 1.59 1.01-2.51 0.047
Age (y) 0.99 0.97-1.01 0.268
BMI (kg/m2) 0.99 0.94-1.04 0.653
Other pain (yes) 1.18 0.79-1.78 0.419
Anxiety (yes) 0.94 0.86-1.03 0.190
Depression (yes) 1.04 0.99-1.07 0.064
Maximum pain intensity NRS 5 10
Unadjusted model
CPSNP (yes) 2.09 1.13-3.89 0.019
Fully adjusted* model
CPSNP (yes) 2.12 1.11-4.07 0.023
Age (y) 0.97 0.94-0.99 0.020
BMI (kg/m2) 0.95 0.89-1.02 0.188
Other pain (yes) 0.89 0.50-1.58 0.689
Anxiety (yes) 0.93 0.82-1.05 0.234
Depression (yes) 1.05 0.99-1.11 0.090
* Adjusted for age, BMI, other pain of at least moderate intensity (yes/no), depression (yes/no, cutoff$19 in
BDI II), and anxiety (yes/no, cutoff $11 in HADS-A). P values , 0.05 are shown in bold.
BDI II, Beck’s Depression Inventory II; BMI, body mass index; CI, confidence interval; CPSNP, chronic
postsurgical neuropathic pain; HADS-A, Hospital Anxiety-Depression Scale-Anxiety; HR, hazard ratio.
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[15] Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H.
Prevalence of and factors associated with persistent pain following breast
cancer surgery. JAMA 2009;302:1985–92.
[16] Haroutiunian S, Nikolajsen L, Finnerup NB, Jensen TS. The neuropathic
component in persistent postsurgical pain: a systematic literature review.
PAIN 2013;154:95–102.
[17] Ilhan E, Chee E, Hush J,Moloney N. The prevalence of neuropathic pain is
high after treatment for breast cancer: a systematic review. PAIN 2017;
158:2082–91.
[18] Jo M, Kim JH, Song GJ, Seo M, Hwang EM, Suk K. Astrocytic
orosomucoid-2 modulates microglial activation and neuroinflammation.
J Neurosci 2017;37:2878–94.
[19] Johansen A, Schirmer H, Stubhaug A, Nielsen CS. Persistent post-
surgical pain and experimental pain sensitivity in the Tromsø study:
comorbid pain matters. PAIN 2014;155:341–8.
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